Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-133763

Published: 2020

Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1596.

https://doi.org/10.1182/blood-2019-126086

Published: 2019

Journal Articles

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, Heather A. Rasmussen, BS, Pamela S. Becker, MD, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2018-99-115476

Published: 2018

Journal Articles

Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL

Prathima Reddy, MD, Alexandra Sokolova, MD, Victor A. Chow, MD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Brian G. Till, MD, Andrei R Shustov, MD, Edus H. Warren, MD PhD, Manoj P. Menon, MD, Sandra Kanan, MSN, ARNP, Yolanda D. Tseng, MD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2018) 132 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2018-99-119794

Published: 2018

Journal Articles

Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Solomon A. Graf, MD, Ryan C. Lynch, MD, David G. Coffey, MD, Mazyar Shadman, MD MPH, Sandra Kanan, MSN, ARNP, Edward N. Libby, III, MD, Edus H. Warren, MD PhD, Colin Godwin, Ted Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 5326.

https://doi.org/10.1182/blood-2018-99-117572

Published: 2018

Journal Articles

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Victor A. Chow, MD, Ajay K. Gopal, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R. Shustov, MD, Manoj P. Menon, MD, Sandra Kanan, MSN, ARNP, Utkarsh H. Acharya, DO, Erin Mullane, DNP, Lindsay M. Hannan, MD MS, Jenna M. Voutsinas, MSc, Ted Gooley, PhD, Ryan C. Lynch, MD

Blood (2018) 132 (Supplement 1): 94.

https://doi.org/10.1182/blood-2018-99-110747

Published: 2018

Journal Articles

Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Stephen D. Smith, MD, Ryan C. Lynch, MD, Brian G. Till, MD, Andrew J. Cowan, MD, Qian V. Wu, PhD, Jenna M. Voutsinas, MSc, Mazyar Shadman, MD MPH, Katie Blue, Andrei R. Shustov, MD, Sandra Kanan, MSN, ARNP, Lauren Low, PA-C, Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2018-99-119129

Published: 2018

NARROW

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL

Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL

Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only